P

Prime Medicine

Develops Prime Editing gene therapies

Senior Associate Scientist 2 - On-Target NGS

Translational Research & Bench BiologyPosted on Nov 13
Full-timeCambridge, MA, USAIn-person

About the Job

Requirements

  • A scientific degree in molecular biology, biotechnology, or another relevant scientific field is required.
  • At least 4 years of hands-on experience in next-generation sequencing library preparation and sequencing are required.
  • At least 2 years of experience in a good manufacturing practice laboratory are required.
  • Technical experience with Illumina sequencing platforms is required.
  • Experience using a laboratory information management system for sample tracking, processing, and experimental documentation is required.
  • Attention to detail and commitment to producing high-quality next-generation sequencing data are required.

Responsibilities

  • Support the execution, development, and validation of good manufacturing practice and research and development next-generation sequencing workflows.
  • Operate, regularly maintain, and troubleshoot automated liquid handlers and Illumina sequencers.
  • Track and document instrument maintenance, next-generation sequencing reagents, samples, and sequencing quality-control metrics in laboratory information management systems.
  • Collaborate with research and development scientists, automation, informatics, and bioinformatics teams to execute research and development sample submissions using high-throughput next-generation sequencing.
  • Drive the transition of assays from development to production by working with members of the research and development and automation teams.
  • Perform other related duties and ad hoc projects as required by the position and in support of the On-Target next-generation sequencing team.

Desired Qualifications

  • Experience with laboratory automation, particularly next-generation sequencing on liquid handlers, is a plus.
  • Assay validation and implementation experience is a plus.

About the Company

Prime Medicine

Develops Prime Editing gene therapies

Prime Medicine develops gene-editing therapies designed to treat a wide range of genetic diseases. The company utilizes a specific technology called "Prime Editing," which acts like a DNA word processor. This system can search for a specific location in the genetic code and replace a faulty segment of DNA with a corrected version, restoring normal function to the gene. Unlike earlier gene-editing methods like CRISPR-Cas9, which often create double-stranded breaks in DNA that can lead to unpredictable insertions or deletions, Prime Editing makes precise changes without breaking both strands of the DNA helix. This approach allows for more control over the final genetic sequence and reduces the risk of unintended mutations. The company’s goal is to create one-time curative treatments that can halt or prevent genetic disorders, providing lifelong health benefits to patients by addressing the root cause of their conditions at the molecular level.

Company size
51-200
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2019

Recently Posted Jobs

Explore more opportunities at Prime Medicine

See more jobs